GlassScriptPhysician profile
Andrew D Lee
NPI 1518154889
$702,435.87
in general payments reported to CMS, 2019-2025
25 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $28K · 2021: $70K · 2022: $122K · 2023: $128K · 2024: $131K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $323K · Travel and Lodging: $20K · Honoraria: $17K · Food and Beverage: $11K · Consulting Fee: $4,304 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $323,038.50 |
| Travel and Lodging | $19,877.82 |
| Honoraria | $17,400.00 |
| Food and Beverage | $10,606.22 |
| Consulting Fee | $4,304.00 |
| Education | $253.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $263,197.86 | 2019-2025 | |
| Amgen INC. | $101,739.15 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $97,388.15 | 2022-2024 | Vtama |
| Genzyme Corporation | $64,678.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $55,457.99 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $46,597.89 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $26,674.63 | 2022-2025 | Opzelura, Opzelura |
| Celgene Corporation | $25,316.51 | 2019 | |
| Organon LLC | $18,581.84 | 2025 | Vtama |
| Janssen Biotech, INC. | $1,166.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $332.25 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $274.72 | 2019-2024 | |
| Ucb, INC. | $217.44 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.70 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Lilly USA, LLC | $150.00 | 2019-2025 | Taltz, Ebglyss, Olumiant |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.48 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $91.10 | 2019-2023 | Winlevi |
| E.R. Squibb & Sons, L.L.C. | $64.53 | 2022-2025 | Sotyktu |
| Epi Health, LLC | $46.93 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $41.10 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $36.52 | 2024-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $18.50 | 2024 | |
| Almirall LLC | $17.66 | 2019 | |
| Dermira, INC. | $16.86 | 2019 | |
| Aclaris Therapeutics, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.